title: Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
abstract: We studied the safety and immunogenicity of a Shigella flexneri 2a vaccine comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins-proteosomes-in normal, healthy adults. A two-dose series of immunizations was given by intranasal spray, and doses of 0.1, 0.4, 1.0, and 1.5 mg (based on protein) were studied in a dose-escalating design. The vaccine was generally well tolerated. The most common reactions included rhinorrhea and nasal stuffiness, which were clearly dose related (P < or = 0.05). These reactions were self-limited and generally mild. The vaccine elicited S. flexneri 2a LPS-specific immunoglobulin A (IgA), IgG, and IgM antibody-secreting cells (ASCs) in a dose-responsive manner. At doses of 1.0 or 1.5 mg, highly significant (P < 0.001) increases in ASCs of all antibody isotypes occurred and 95% of subjects had an ASC response in at least one antibody isotype. Dose-related serum antibody responses were observed, with geometric mean two- to fivefold rises in specific serum IgA and IgG titers and two- to threefold rises in IgM in the 1.0- and 1.5-mg-dose groups (P < 0.0001 for each isotype). Elevated serum antibody levels persisted through day 70. Increases in fecal IgG and IgA and also in urinary IgA specific for S. flexneri 2a LPS were demonstrated. These were most consistent and approached statistical significance (P = 0.02 to 0.12 for various measures) on day 70 after the first dose. The magnitude of immune responses to intranasally administered proteosome-S. flexneri 2a LPS vaccine is similar to those reported for live vaccine candidates associated with protective efficacy in human challenge models, and further evaluation of this product is warranted.
authors.affiliation: Intellivax, Inc., Baltimore, Maryland 21227, USA. lfries@intellivax.com
authors.forename: L F
authors.initials: LF
authors.lastname: Fries
authors.forename: A D
authors.initials: AD
authors.lastname: Montemarano
authors.forename: C P
authors.initials: CP
authors.lastname: Mallett
authors.forename: D N
authors.initials: DN
authors.lastname: Taylor
authors.forename: T L
authors.initials: TL
authors.lastname: Hale
authors.forename: G H
authors.initials: GH
authors.lastname: Lowell
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D000921:Antibody-Producing Cells / Q000276:immunology; D003257:Consumer Product Safety; D005243:Feces; D005260:Female; D006304:Health Status; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000276:immunology; D022281:Shigella Vaccines / Q000276:immunology*; D012763:Shigella flexneri / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D008070:Lipopolysaccharides; D022281:Shigella Vaccines